N. U. Nair

This paper describes a silk-based platform that stabilizes PAL for oral enzyme replacement therapy in PKU patients.

The paper identifies a 48-gene prognostic signature and synthetic-lethality profiles predictive of survival and therapy response in mesothelioma using transcriptomic and exomic data from 122 patients.

This study identifies sequence-function relationships in PAL through deep mutational scanning and characterizes mechanisms of activity enhancement.

The paper identifies synergistic drug combinations in non-small-cell lung cancer cell lines, finding that synergy often arises from sensitizing resistant models through dual pathway targeting.

The paper identifies cancer-resistance associated genes across species and finds their relevance to human cancer risk through conservation analysis and functional studies.

This study engineers lactobacilli to suppress Pseudomonas aeruginosa biofilm formation and viability using a pathogen-derived enzyme.

This paper expresses and characterizes the PGA Synthetase complex in E. coli, showing its membrane localization and activity, and reports higher PGA production compared to Bacillus subtilis.

The paper quantifies synthetic lethality in normal tissues and links it to cancer risk, onset, and tumor suppressor specificity using GTEx transcriptomics data.

The paper develops a kinetic model to evaluate orally delivered living therapeutics, adapting traditional PK-PD models for engineered bacteria in phenylketonuria treatment.

This study uses directed evolution to engineer PAL enzymes from Anabaena variabilis, identifying mutations that enhance activity.

This paper predicts patient response to cancer therapies using computationally derived genetic interactions across multiple tumor transcriptomics datasets.

The paper develops an in vitro assay to measure mucus adhesion of probiotics and demonstrates engineering strategies to control mucoadhesive properties.

This paper improves the catalytic efficiency of LsLAI for tagatose biosynthesis by encapsulating it in a permeabilized bacterium, achieving high conversion and stability.

The paper predicts synthetic rescue mediators of resistance to targeted and immunotherapy using tumor transcriptomics and survival data from 10,000 TCGA patients, validating predictions through experimental screens.